Anti-Rheumatic Drugs - Germany

Germany

The Anti-Rheumatic Drugs market in Germany is expected to witness a revenue downturns in the coming years.
According to projections, the revenue in this market is estimated to reach €0.95bn euros by the year 2024.
Moreover, it is anticipated that the market will experience a steady annual growth rate of 0.83% between 2024 and 2029.
This growth is expected to result in a market volume of approximately €0.99bn euros by 2029.
When compared globally, United States is forecasted to generate the highest revenue in the Anti-Rheumatic Drugs market.
In the year 2024 alone, United States is projected to generate a revenue of €32,180.00m.
Germany is a leading market for anti-rheumatic drugs, with a strong emphasis on research and development for innovative treatment options.

Key regions: Germany, United States, India, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Rheumatic Drugs market in Germany has experienced significant growth in recent years.

Customer preferences: German customers prefer high-quality and effective anti-rheumatic drugs that can alleviate pain and improve their quality of life. They are willing to pay a premium for innovative drugs that can provide better outcomes than traditional treatments. Additionally, customers in Germany are increasingly interested in natural and alternative treatments for rheumatoid arthritis, leading to a rise in demand for herbal remedies and supplements.

Trends in the market: One of the major trends in the Anti-Rheumatic Drugs market in Germany is the increasing use of biologic drugs. Biologics are a type of medication that is made from living organisms and are highly effective in treating rheumatoid arthritis. The demand for biologics has been driven by their superior efficacy compared to traditional treatments, as well as their ability to slow the progression of the disease.Another trend in the market is the growing use of biosimilars. Biosimilars are drugs that are highly similar to biologics and are used to treat the same conditions. They are often less expensive than biologics, making them an attractive option for patients and healthcare providers. The use of biosimilars has been encouraged by the German government, which has implemented policies to promote their use in an effort to reduce healthcare costs.

Local special circumstances: Germany has a well-developed healthcare system that provides universal coverage to its citizens. This has led to a high level of access to healthcare services, including anti-rheumatic drugs. Additionally, Germany has a large aging population, which has contributed to the growth of the Anti-Rheumatic Drugs market. Rheumatoid arthritis is more common in older adults, and as the population ages, the demand for anti-rheumatic drugs is expected to continue to rise.

Underlying macroeconomic factors: The German economy has been growing steadily in recent years, which has contributed to the growth of the Anti-Rheumatic Drugs market. A strong economy means that more people have access to healthcare services, and are able to afford expensive treatments like biologics. Additionally, Germany has a strong pharmaceutical industry, which has led to the development of innovative new drugs for the treatment of rheumatoid arthritis. This has helped to drive growth in the market by providing patients with new treatment options.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.